CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $8,000 | +60.0% | 1,580 | +102.6% | 0.00% | +100.0% |
| Q3 2020 | $5,000 | -16.7% | 780 | -11.4% | 0.00% | -50.0% |
| Q2 2020 | $6,000 | -25.0% | 880 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $8,000 | -55.6% | 880 | -40.5% | 0.00% | -40.0% |
| Q4 2019 | $18,000 | +350.0% | 1,480 | +48.0% | 0.01% | +400.0% |
| Q3 2019 | $4,000 | -75.0% | 1,000 | 0.0% | 0.00% | -75.0% |
| Q2 2019 | $16,000 | -38.5% | 1,000 | 0.0% | 0.00% | -42.9% |
| Q1 2019 | $26,000 | +44.4% | 1,000 | 0.0% | 0.01% | +16.7% |
| Q4 2018 | $18,000 | -75.0% | 1,000 | -58.3% | 0.01% | -72.7% |
| Q3 2018 | $72,000 | -34.5% | 2,400 | 0.0% | 0.02% | -35.3% |
| Q2 2018 | $110,000 | -99.9% | 2,400 | +4.3% | 0.03% | -12.8% |
| Q1 2018 | $121,440,000 | -22.4% | 2,300 | 0.0% | 0.04% | -22.0% |
| Q4 2017 | $156,400,000 | +18.6% | 2,300 | +43.8% | 0.05% | +13.6% |
| Q3 2017 | $131,840,000 | +40.8% | 1,600 | +60.0% | 0.04% | +69.2% |
| Q2 2017 | $93,630,000 | – | 1,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |